INNOCARE - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

does not make any representation about the accuracy or completeness of this announcement and expressly disclaims any liability arising out of or in connection with all or any part of this announcement. We accept no liability for any loss caused by reliance on such content.

InnoCare Pharma Limited Nuocheng Jianhua Pharmaceutical Co., Ltd.

(Incorporated in the Cayman Islands with limited liability) (Stock code: 9969)

Overseas regulatory announcement

This announcement is made by InnoCheng Jianhua Pharmaceutical Co., Ltd. (the "Company") pursuant to the Securities and Exchange Commission of The Stock Exchange of Hong Kong Limited.

Made in accordance with Rule 13.10B of the Securities Listing Rules.

This is to set forth the "Announcement on Board Resolutions" and "About 2023" published by the Company on the website of the Shanghai Stock Exchange. The third vesting period of the initial grant portion of the Science and Technology Innovation Board restricted stock incentive plan and the second vesting period of the reserved grant portion Announcement on Compliance with vesting conditions during the vesting period", "Announcement on the invalidation of some restricted shares that have been granted but have not vested yet" "Announcement on the Use of Idle Own Funds for Cash Management", "Announcement on the Use of Idle Own Funds for Cash Management", "Announcement on the 2026 Science and Technology Innovation Self-examination report on the insider trading of the company's stocks under the restricted stock incentive plan, "2026

List of first grant incentive objects of the Science and Technology Innovation Board Restricted Stock Incentive Plan (as of the date of first grant)", "The Compensation Committee of the Board of Directors Regarding the Initial Grant of Part III of the 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan" Verification Opinions on the Vesting Period and the Vesting List of the Reserved Part for the Second Vesting Period", "Board of Directors Remuneration" The Committee’s verification of the list of first-time incentive recipients under the 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan Opinions", "Shanghai Fangda Law Firm's Opinions on InnoCare Pharma Limited) 2025 Annual General Meeting of Shareholders”, “Shanghai Fangda Law Firm’s Legal Opinion on No.

InnoCare Pharma Limited 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan The third vesting period of the planned initial grant part and the second vesting period of the reserved grant part vesting condition achievements and Legal Opinions on Matters Related to the Invalidation of Partial Restricted Stocks" and "Shanghai Fangda Law Firm's Legal Opinions on InnoCare Pharma Limited 2026 Science and Technology Innovation Board Restricted Stock Incentive "Legal Opinion on Matters Related to the First Grant of the Plan".

By order of the board of directors

Nuocheng Jianhua Pharmaceutical Co., Ltd. Chairman and Executive Director Dr. Cui Jisong

Hong Kong, June 16, 2026

As at the date of this announcement, the Board of Directors includes Dr. Cui Jisong, Chairman and Executive Director; Dr. Zhao Renbin, Executive Director; Non-executive Directors

Dr. Shi Yigong and Mr. Xie Ronggang; and independent non-executive directors Ms. Hu Lan, Dr. Dong Dandan and Professor Guan Kunliang.

Remuneration Committee of the Board of Directors of InnoCheng Jianhua Pharmaceutical Co., Ltd.

About the 2019 Science and Technology Innovation Board Restricted Stock Incentive Plan 2026

Verification Opinions on the List of Incentive Objects Granted for the First Time

The Remuneration Committee of the Board of Directors of InnoCheng Jianhua Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") complies with the "China

Company Law of the People's Republic of China (hereinafter referred to as the "Company Law"), Securities Law of the People's Republic of China,

"Measures for the Administration of Equity Incentives of Listed Companies" (hereinafter referred to as "the "Administration Measures"), "Shanghai Securities Exchange Exchange Listing Rules for Stocks on the Science and Technology Innovation Board (hereinafter referred to as the "Listing Rules"), "Companies Listed on the Science and Technology Innovation Board"

Self-regulatory Guidelines No. 4 - Equity Incentive Information Disclosure" and other relevant laws, regulations and normative documents

Relevant regulations stipulate that the company's 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan (hereinafter referred to as the "Incentive Plan")

The list of first-time incentive recipients will be reviewed and the verification opinions will be issued as follows:

1. None of the incentive objects granted for the first time by the company’s incentive plan are prohibited from doing so as stipulated in the “Administration Measures”. Situations that become the target of incentives:

(1) Determined as an unsuitable candidate by the stock exchange within the last 12 months;

(2) Have been deemed as inappropriate candidates by the China Securities Regulatory Commission and its dispatched agencies within the last 12 months;

(3) Administrative punishment by the China Securities Regulatory Commission and its dispatched agencies due to serious violations of laws and regulations in the past 12 months

impose fines or take market entry ban measures; (4) Those who are prohibited from serving as company directors or senior managers as stipulated in the Company Law;

(5) Laws and regulations prohibit participation in equity incentives of listed companies;

(6) Other circumstances determined by the China Securities Regulatory Commission.

2. The incentive objects granted for the first time under this incentive plan do not include independent non-executive directors of the company, and do not include individual directors.

Shareholders or actual controllers who individually or collectively hold more than 5% of the company's shares and their spouses, parents, and children. Ben The incentive objects of the incentive plan all meet the conditions for incentive objects stipulated in the "Administrative Measures" and "Listing Rules" and meet the requirements of

According to the scope of incentive objects stipulated in the company's incentive plan, they are the main subjects of the incentive objects of the company's incentive plan.

The qualification is legal and valid; the first grant conditions stipulated in this incentive plan have been met, and it is agreed to be determined in 2026

June 16, 2017 is the first grant date, and the grant will be granted to 100 people who meet the grant conditions at a grant price of RMB 14.47 per share.

The incentive objects were granted 8 million restricted shares. In summary, the Remuneration Committee of the Company’s Board of Directors believes that inclusion in the list of first-time incentive recipients under this incentive plan

All personnel meet the conditions stipulated in relevant laws, regulations and normative documents, and comply with the company's "2026 Science and Technology Plan"

The conditions for incentive objects stipulated in the GEM Restricted Stock Incentive Plan (Draft), which serve as the first step of this incentive plan.

The incentive objects awarded for the first time are legal and valid; the conditions for the first award stipulated in this incentive plan have been met, and the agreement is confirmed. June 16, 2026 is set as the first grant date, and the grant price will be 14.47 yuan/share to 100 qualified candidates.

The incentive objects subject to the grant conditions are granted 8 million restricted shares.

(No text below)

Nuocheng Jianhua Pharmaceutical Co., Ltd.

Board Compensation Committee

June 16, 2026